FDA Launches READI-Home Innovation Challenge: Opportunities—and Tensions—for Home-Use Device Developers

On April 7, 2026, FDA’s Center for Devices and Radiological Health (CDRH) announced the READI-Home Innovation Challenge: Reducing Readmissions through Device Innovation for the Home, part of its broader Home as a Health Care Hub initiative. The program is intended to accelerate patient access to medical devices that support post-discharge care and reduce hospital readmissions.

For device developers, the Challenge offers a new pathway for early and iterative FDA engagement. At the same time, it highlights ongoing tensions in FDA’s regulatory approach to home-use technologies, particularly for diagnostic and specimen collection devices.

Program Overview

The READI-Home Innovation Challenge is designed to promote development of devices that enable monitoring, treatment, and recovery in the home in order to reduce hospital readmission rates, with a focus on technologies used by patients and caregivers rather than healthcare professionals.

The program includes two phases:

• Selection Phase (April 7 – September 30, 2026):
  Sponsors submit an informational Q-Submission describing the device, development status, and anticipated clinical impact.
• Interaction Phase (beginning December 5, 2026):
  Up to nine selected devices (no more than one per manufacturer) will receive enhanced FDA engagement, including “sprint”-style discussions and more frequent feedback on device design and testing for home use.

Submission Expectations

Submissions are limited to 16 pages (including a one-page executive summary, exclusive of references) and must address:

• Device description and clinical need;
• Novelty of the device;
• Current development status of the device;
• Data development plan, including information for both clinical and non-clinical completed and planned testing;
• Team expertise; and
• Anticipated impact, specifically, how the device is expected to significantly improve the benefit-risk profile of a treatment or diagnostic compared to alternatives for the identified disease or condition.

FDA will prioritize devices that:

• Address unmet needs in the home setting;
• Are intended for patient and/or caregiver use;
• Can be deployed by the patient without continuous clinical supervision;
• Have supporting evidence suggesting potential to reduce readmissions; and
• Have sufficient evidence to demonstrate feasibility.

Key Takeaways for Sponsors

1. Earlier FDA Engagement

The Challenge provides a structured opportunity for early interaction with FDA. Sponsors should be prepared to engage with a well-developed regulatory and evidence strategy, including a clear articulation of how the device may impact readmission rates.

2. Increased Focus on Home-Use Considerations

Devices will be evaluated through a home-use lens, presumably with an emphasis on:

• Human factors and usability
• Labeling and instructions for lay users
• Performance in uncontrolled environments

3. Opportunity to Align with Expedited Programs

Participation may facilitate consideration for programs such as the Breakthrough Devices Program or Safer Technologies Program (STeP), creating potential downstream regulatory advantages.

A Broader Regulatory Tension

The READI-Home Innovation Challenge reflects FDA’s growing emphasis on expanding care delivery in the home and supporting innovation in this space. However, it also underscores an ongoing challenge for sponsors: inconsistent application of regulatory flexibility across categories of home-use devices.

In particular, developers of home specimen collection and diagnostic devices have continued to face significant evidentiary expectations, driven by concerns regarding variable home environments and lay user performance. These expectations often translate into extensive usability, stability, and method comparison data requirements.

While FDA has emphasized its commitment to the statutory “least burdensome” standard, there remains limited guidance on how that principle is applied in the context of home-use diagnostics.

Conclusion

The READI-Home Innovation Challenge presents a valuable opportunity for device developers to engage early with FDA and shape regulatory strategy for home-use technologies aimed at reducing readmissions.

At the same time, sponsors should be aware that regulatory expectations for home-use devices remain complex and, in some areas, evolving. Careful planning—particularly with respect to clinical evidence, human factors, and real-world use conditions—will be critical to success.

How We Can Help

We can assist clients in preparing their submissions for the READI-Home Innovation Challenge, developing regulatory and clinical strategies for home-use devices more broadly, and assessing eligibility for FDA programs such as the Breakthrough Devices program or STeP.

Please contact us if you have questions about the READI-Home Innovation Challenge or would like assistance preparing a submission.